Oxbow Advisors LLC Purchases New Stake in Medpace Holdings, Inc. $MEDP

Key Points

• Oxbow Advisors acquired 9,208 Medpace shares in the second quarter, valued at approximately $4.9 million. Institutional investors and hedge funds collectively own 77.98% of MEDP.
• Analysts remain cautious overall, with a consensus “Hold” rating and an average price target of $584.18, despite several firms raising their targets to as high as $665.
• Medpace exceeded quarterly expectations, reporting $4.25 EPS and $707.33 million in revenue, with revenue up 17.2% year over year. Shares opened at $590.30, while insiders have sold nearly $38 million worth of stock over the past 90 days.

Oxbow Advisors LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,208 shares of the company's stock, valued at approximately $4,876,000.

A number of other large investors have also recently bought and sold shares of MEDP. California State Teachers Retirement System increased its stake in Medpace by 22.1% in the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company's stock valued at $12,505,000 after acquiring an additional 4,719 shares during the last quarter. Cerity Partners LLC lifted its stake in Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company's stock worth $45,478,000 after purchasing an additional 23,530 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new stake in Medpace during the second quarter worth $1,685,000. Northwestern Mutual Wealth Management Co. lifted its stake in Medpace by 24,930.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company's stock worth $56,936,000 after purchasing an additional 100,968 shares during the last quarter. Finally, Mitchell Capital Management Co. acquired a new stake in shares of Medpace in the 4th quarter valued at $3,383,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on MEDP shares. TD Cowen lifted their price target on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Mizuho upped their price objective on Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Finally, Truist Financial boosted their target price on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $584.18.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 458 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total value of $274,978.62. Following the completion of the transaction, the chief executive officer directly owned 603,978 shares in the company, valued at approximately $362,622,351.42. This represents a 0.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company's stock, valued at $9,154,350. The trade was a 44.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 67,195 shares of company stock valued at $37,989,998. 20.50% of the stock is owned by insiders.

Medpace Trading Down 1.1%

Shares of MEDP stock opened at $590.30 on Wednesday. The firm has a market capitalization of $16.48 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.58 and a beta of 1.15. The business's 50-day moving average price is $541.49 and its 200-day moving average price is $491.49. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm's revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source